lu177 monoclonal antibody j591
mAbexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2004 (NCT00081172)
Timeline
Indications
Studied for
Mechanism of action
- Glutamate carboxypeptidase IIINHIBITOR
FOLH1 inhibitor
- Glutamate carboxypeptidase IIImmunity, passive
FOLH1 immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- 177-Lutetium
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109557 ↗
Also known as
- lu177 monoclonal antibody j591
- mln-591rl
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03545165 | Phase 1/Phase 2 (Phase 2) | Apr 18, 2018 | Cornell University |
| NCT00081172 | Phase 2 | Jan 1, 2004 | Cornell University, National Cancer Institute (NCI) |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cornell University | Academic/Hospital | 2 | 2 | 1 | 2004 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2004 |
2 organizations
Page 1 / 1